Trilaciclib
- Generic Name
- Trilaciclib
- Brand Names
- Cosela
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30N8O
- CAS Number
- 1374743-00-6
- Unique Ingredient Identifier
- U6072DO9XG
- Background
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
- Indication
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.
- Associated Conditions
- Bone Marrow Suppression caused by Chemotherapy
- Associated Therapies
- -
Treatments in Clinical Trials for Small Cell Lung Cancer
Small cell lung cancer (SCLC) often responds well initially but later relapses. New treatments like Imdelltra, Trilaciclib, Durvalumab, and Lurbinectedin have been FDA approved. Clinical trials are ongoing for treatments like Ivonescimab, PM8002, Adebelimab, IBI3009, YL201, ZG006, and Tarlatamb, focusing on extensive stage SCLC.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath